Genmab A/S

GMAB

Add to Watchlist

26.575USD

-0.515-1.90%

Market hours （ET）Quotes delayed by 15 min

Genmab A/S's Score

Industry at a Glance

Industry Ranking

17 / 383

Overall Ranking

107 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Genmab A/S Highlights

StrengthsRisks

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 55.58% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.72B.

Overvalued

The company’s latest PE is 20.41, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.31M shares, decreasing 3.87% quarter-over-quarter.

Held by Mairs and Power

Star Investor Mairs and Power holds 8.09K shares of this stock.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

38.923

Target Price

+47.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Genmab A/S is 8.94, ranking 19 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 896.00M, representing a year-over-year increase of 25.31%, while its net profit experienced a year-over-year increase of 72.82%.

Score

Industry at a Glance

Previous score

8.94

Change

0



Financials

7.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.89

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.67

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Genmab A/S is 8.00, ranking 68 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is 20.41, which is 0.00% below the recent high of 20.41 and 95.06% above the recent low of 1.01.

Score

Industry at a Glance

Previous score

8.00

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Genmab A/S is 8.57, ranking 97 out of 383 in the Biotechnology & Medical Research industry. The average price target is 34.70, with a high of 48.00 and a low of 23.50.

Score

Industry at a Glance

Previous score

8.57

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Genmab A/S is 7.23, ranking 116 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.22 and the support level at 25.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.84

Change

0.39

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Genmab A/S is 3.00, ranking 193 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.10%, representing a quarter-over-quarter increase of 13.72%. The largest institutional shareholder is James Simons, holding a total of 3.49M shares, representing 0.57% of shares outstanding, with 59.29% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Orbis Investment Management Ltd.

14.42M

+30.15%

AllianceBernstein L.P.

10.88M

-0.70%

Paradigm BioCapital Advisors LP

7.04M

+84.44%

Arrowstreet Capital, Limited Partnership

4.98M

+36.64%

BlackRock Institutional Trust Company, N.A.

3.58M

+37.46%

Renaissance Technologies LLC

Star Investors

3.49M

+23.79%

Harding Loevner LP

3.37M

-3.28%

Parametric Portfolio Associates LLC

1.69M

+6.93%

First Trust Advisors L.P.

1.34M

-20.87%

Federated Hermes Global Investment Management Corp.

679.38K

+60.63%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Genmab A/S is 8.54, ranking 4 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Genmab A/S

GMAB

7.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment